The New York Times

The Agriculture Department offered new initiatives for ranchers after President Trump said he would import more beef. The moves aren’t a quick fix.

The U.S. energy giant, which stayed in the country after other Western companies left, will invest $7 billion in the country to more than double its production there.

U.S. and Iranian forces traded attacks again, pushing oil prices higher as bond yields remained elevated.

A new U.S. survey anticipates an average increase of 11 percent unless benefits are cut, the highest rate in decades. Other findings also predict a sharp rise.

If you own bonds, they may be in a broad fund that hasn’t lost much money. And that fund may do much better in the next several years.

Nate Silver, Clare Malone and Galen Druke will host “Still Counting,” a nonpartisan politics show — on a decidedly partisan podcast network.

The magazine, famous for publishing Jack London stories and Norman Rockwell art, will continue online.

In times of natural disasters and other dangers, special features tucked away on your iPhone or Android device could help make a difference.

For the first time in a year, the U.S.-Mexico border partly reopened to cattle imports following a screwworm infestation across the region. The battle against the flesh-eating fly has only just begun deep in Mexico.

Initial results showed that residents of Independence, Mo., voted overwhelmingly to recall an official who backed billions of dollars in tax breaks for a data center.

The founder of The Ringer is taking flak for using artificial intelligence to conjure opinions from the deceased film critic Roger Ebert. Ads from OpenAI have recently run on the show.

The Trump administration’s deal with a private oil company to increase oil production in the South American country could take many years to come to fruition.

The ships were hit near Oman on Monday, the latest attacks on vessels in the Persian Gulf. Oil prices rose more than 2 percent.

Novo Nordisk’s chief executive, Mike Doustdar, is a year into a corporate turnaround. He says investors are still underestimating the promise of the company’s drugs.